Furthermore, Cyp17 variant C alelle may increase the breast cancer risk in conjugation with long-term hormone replacemet treatment (HRT) and a high body mass index (BMI) in postmenopausal women (Chen et al., 2008). Here, CYP17A1 is linked to breast carcinoma.